2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Abstract Number: 2266

Serum 1,25(OH)2 Vitamin D and 25(OH) Vitamin D Ratio for the Diagnosis of Sarcoidosis-Related Uveitis
Abstract Number: 2267

Ocular and Systemic Features in 262 Patients with Systemic Sarcoidosis and Its Correlation with Iwos Criteria
Abstract Number: 2268

Anti-IL6-Receptor Tocilizumab in Graves’ Orbitopathy. Multicenter Study of 46 Patients
Abstract Number: 2269

Infliximab Therapy in Refractory Retinal Vasculitis of Behçet’s Disease, Short and Long-Term Follow-up. Multicenter Study of 72 Patients
Abstract Number: 2270

Treatment of Refractory Cystoid Macular Edema to Conventional Immunosuppressive Therapy: Tocilizumab Vs Anti-TNF-Alpha. Multicenter Study of 59 Patients
Abstract Number: 2271

Long-Term Efficacy and Safety of Adalimumab By Immunosuppressant Use in Patients with Non-Infectious Uveitis
Abstract Number: 2272

Missed Opportunity? Evaluation for Systemic Autoimmune Diseases in Patients with Uveitis May Not be Optimal: 5-Year Analysis of Patients Being Seen in a Tertiary Medical Center
Abstract Number: 2273

High Dose Intravenous Methylorednisolone Induces Rapid Improvement in Severe Non-Infectious Uveitis. a Multicenter Study of 120 Patients
Abstract Number: 2274

Refractory and Severe Uveitic Cystoid Macular Edema Improves with Tocilizumab in Different Immune Mediated Diseases
Abstract Number: 2275

Autoimmune Encephalitis with Concomitant Systemic Rheumatologic Auto-Antibodies
Abstract Number: 2276

Risk of Hemorrhagic Strokes in Patients with Adenosine Deaminase 2 Deficiency
Abstract Number: 2277

Colchicine: An Effective Treatment Option for Unclassified Autoinflammatory Diseases in Children
Abstract Number: 2278

Cryopyrinopathy across Generations: Longterm Disease Outcome
Abstract Number: 2279

Therapeutic Value of Canakinumab in Patients with Yao Syndrome
Abstract Number: 2280

Transcriptomic Analysis of Hidradenitis Suppurativa Skin Demonstrates Dysregulation of Antimicrobial Proteins and Inflammatory Pathways

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].